In a groundbreaking development, the PBAC has recommended listing ravulizumab (Ultomiris®) on the PBS for adults with NMOSD, marking a revolutionary step forward in NMOSD care….
The PBAC has recommended a proposed amendment to allow nurse practitioners to prescribe certain MS treatments under the PBS—a game-changer that will dramatically improve access to care, especially in regional…
CEO Rohan Greenland outlines the key activities for 2025, which promises to be another big and productive year for MS Australia and the MS community. Tighten your seat belts!…
MS Australia-supported researchers found autologous haematopoietic stem cell transplantation (AHSCT) has no advantages over natalizumab in treating progressive MS….
The Frontiers in MS Research Symposium showcased cutting-edge advancements in MS prevention, care, and management, fostering collaboration among experts, healthcare professionals, and the MS community to drive meaningful progress and…
MS Australia is bringing together the nation’s top researchers to unlock the complex link between EBV) and MS; with the potential to revolutionise how we treat, prevent, and ultimately cure…
CEO Rohan Greenland reflects on the year’s major developments propelling us towards our key goals – world-leading research, vigorous advocacy, placing lived experience at the heart of all we do,…
A new study highlights the unique housing and support needs of Australians living with MS, offering insights to improve independence and quality of life….
Researchers have found lipids (fats) in cerebrospinal fluid that may help distinguish between NMOSD and MS, as well as track disease progression and treatment effectiveness in MS….
